Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications

由 Zattarin, Emma, Leporati, Rita, Ligorio, Francesca, Lobefaro, Riccardo, Vingiani, Andrea, Pruneri, Giancarlo, Vernieri, Claudio
發表在 Cells (2020)

The Landscape of Actionable Gene Fusions in Colorectal Cancer

由 Pagani, Filippo, Randon, Giovanni, Guarini, Vincenzo, Raimondi, Alessandra, Prisciandaro, Michele, Lobefaro, Riccardo, Di Bartolomeo, Maria, Sozzi, Gabriella, de Braud, Filippo, Gasparini, Patrizia, Pietrantonio, Filippo
發表在 Int J Mol Sci (2019)

The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Tax...

由 Ligorio, Francesca, Fucà, Giovanni, Zattarin, Emma, Lobefaro, Riccardo, Zambelli, Luca, Leporati, Rita, Rea, Carmen, Mariani, Gabriella, Bianchi, Giulia V., Capri, Giuseppe, de Braud, Filippo, Vernieri, Claudio
發表在 Cancers (Basel) (2021)

Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients

由 Ligorio, Francesca, Zambelli, Luca, Bottiglieri, Achille, Castagnoli, Lorenzo, Zattarin, Emma, Lobefaro, Riccardo, Ottini, Arianna, Vingiani, Andrea, Pupa, Serenella M., Bianchi, Giulia V., Capri, Giuseppe, Pruneri, Giancarlo, de Braud, Filippo, Vernieri, Claudio
發表在 Ther Adv Med Oncol (2021)

Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality?

由 Dell’Aquila, Emanuela, Zeppola, Tea, Stellato, Marco, Pantano, Francesco, Scartozzi, Mario, Madaudo, Cristina, Pietrantonio, Filippo, Cremolini, Chiara, Aprile, Giuseppe, Vincenzi, Bruno, Moretto, Roberto, Puzzoni, Marco, Garattini, Silvio Ken, Lobefaro, Riccardo, Tonini, Giuseppe, Santini, Daniele
發表在 Clin Med Insights Oncol (2020)

Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system

由 Prelaj, Arsela, Proto, Claudia, Lo Russo, Giuseppe, Signorelli, Diego, Ferrara, Roberto, Mensah, Mavis, Galli, Giulia, De Toma, Alessandro, Viscardi, Giuseppe, Brambilla, Marta, Lobefaro, Riccardo, Trevisan, Benedetta, Trovò, Francesco, Torri, Valter, Sozzi, Gabriella, Garassino, Marina Chiara, Boeri, Mattia
發表在 Transl Lung Cancer Res (2020)

Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II–III HER2-negative breast cancer: a 10-year, retrospec...

由 Lobefaro, Riccardo, Zattarin, Emma, Nichetti, Federico, Prisciandaro, Michele, Ligorio, Francesca, Brambilla, Marta, Sepe, Pierangela, Corti, Francesca, Peverelli, Giorgia, Ottini, Arianna, Beninato, Teresa, Mazzeo, Laura, Rea, Carmen G., Mariani, Gabriella, de Braud, Filippo, Bianchi, Giulia V., Vernieri, Claudio, Capri, Giuseppe
發表在 Ther Adv Med Oncol (2020)

Oral Capecitabine-Vinorelbine Is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cance...

由 Vernieri, Claudio, Prisciandaro, Michele, Nichetti, Federico, Lobefaro, Riccardo, Peverelli, Giorgia, Ligorio, Francesca, Zattarin, Emma, Cona, Maria Silvia, Sepe, Pierangela, Corti, Francesca, Manglaviti, Sara, Brambilla, Marta, Re, Barbara, Belfiore, Antonino, Pruneri, Giancarlo, Celio, Luigi, Mariani, Gabriella, Bianchi, Giulia Valeria, Rivoltini, Licia, Capri, Giuseppe, de Braud, Filippo
發表在 Cancers (Basel) (2020)

Clinical Behavior and Treatment Response of Epstein‐Barr Virus‐Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials

由 Corallo, Salvatore, Fucà, Giovanni, Morano, Federica, Salati, Massimiliano, Spallanzani, Andrea, Gloghini, Annunziata, Volpi, Chiara Costanza, Trupia, Desirè Viola, Lobefaro, Riccardo, Guarini, Vincenzo, Milione, Massimo, Cattaneo, Laura, Antista, Maria, Prisciandaro, Michele, Raimondi, Alessandra, Sposito, Carlo, Mazzaferro, Vincenzo, de Braud, Filippo, Pietrantonio, Filippo, Di Bartolomeo, Maria
發表在 Oncologist (2020)